Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746121 | 1.00 | LMNA (0.41) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4929048 | 0.99 | LMNA (0.40) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6203470 | 0.99 | LMNA (0.40) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL7676015 | 0.93 | LMNA (0.42) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6764944 | 0.92 | LMNA (0.41) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL5103621 | 0.89 | LMNA (0.39) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7234943 | 0.88 | LMNA (0.39) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL5111854 | 0.86 | LMNA (0.38) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL5113554 | 0.86 | LMNA (0.38) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL6777770 | 0.86 | LMNA (0.38) | LMNACA2SMN1; SMN2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381614-B1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE | WYETH CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7008944-B2 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-Dioxino[2,3-f]quinoxaline | WYETH (US) | 2006-03-07 | — | — | US | disclosed |
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | WYETH | 2004-04-22 | — | — | US | disclosed |
| EP-1381614-A2 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-f]QUINOXALINE | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6617327-B2 | For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-09-09 | — | — | US | disclosed |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002088144-A2 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE | WYETH (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077652-A1 | Treating obsessive compulsive disorder, panic attacks, sexual disorders, eating disorders, obesity, drug abuse and ethanol or cocaine dependence; anxiolytic agents | OPRD1, DRD1, ADH1A | LMNA 4618/4885CA2 4525/4885SMN1; SMN2 3763/4885 |
| US-20020183329-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline | OPRD1, OPRK1, DRD2 | LMNA 4332/4885CA2 4385/4885SMN1; SMN2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.